Search Results - "Cejas, Paloma"

Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer by Cejas, Paloma, Xie, Yingtian, Font-Tello, Alba, Lim, Klothilda, Syamala, Sudeepa, Qiu, Xintao, Tewari, Alok K., Shah, Neel, Nguyen, Holly M., Patel, Radhika A., Brown, Lisha, Coleman, Ilsa, Hackeng, Wenzel M., Brosens, Lodewijk, Dreijerink, Koen M. A., Ellis, Leigh, Alaiwi, Sarah Abou, Seo, Ji-Heui, Baca, Sylvan, Beltran, Himisha, Khani, Francesca, Pomerantz, Mark, Dall’Agnese, Alessandra, Crowdis, Jett, Van Allen, Eliezer M., Bellmunt, Joaquim, Morrisey, Colm, Nelson, Peter S., DeCaprio, James, Farago, Anna, Dyson, Nicholas, Drapkin, Benjamin, Liu, X. Shirley, Freedman, Matthew, Haffner, Michael C., Corey, Eva, Brown, Myles, Long, Henry W.

“…Neuroendocrine carcinomas (NEC) are tumors expressing markers of neuronal differentiation that can arise at different anatomic sites but have strong…”
Get full text

MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets by Qiu, Xintao, Boufaied, Nadia, Hallal, Tarek, Feit, Avery, de Polo, Anna, Luoma, Adrienne M., Alahmadi, Walaa, Larocque, Janie, Zadra, Giorgia, Xie, Yingtian, Gu, Shengqing, Tang, Qin, Zhang, Yi, Syamala, Sudeepa, Seo, Ji-Heui, Bell, Connor, O’Connor, Edward, Liu, Yang, Schaeffer, Edward M., Jeffrey Karnes, R., Weinmann, Sheila, Davicioni, Elai, Morrissey, Colm, Cejas, Paloma, Ellis, Leigh, Loda, Massimo, Wucherpfennig, Kai W., Pomerantz, Mark M., Spratt, Daniel E., Corey, Eva, Freedman, Matthew L., Shirley Liu, X., Brown, Myles, Long, Henry W., Labbé, David P.

“…c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression. Although MYC is overexpressed in both early and metastatic disease and…”
Get full text

Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis by Hur, Keun, Cejas, Paloma, Feliu, Jaime, Moreno-Rubio, Juan, Burgos, Emilio, Boland, C Richard, Goel, Ajay

“…Hypomethylation of LINE-1 elements has emerged as a distinguishing feature in human cancers. Limited evidence indicates that some LINE-1 elements encode an…”
Get more information

In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target by Wang, Xiaoqing, Tokheim, Collin, Gu, Shengqing Stan, Wang, Binbin, Tang, Qin, Li, Yihao, Traugh, Nicole, Zeng, Zexian, Zhang, Yi, Li, Ziyi, Zhang, Boning, Fu, Jingxin, Xiao, Tengfei, Li, Wei, Meyer, Clifford A., Chu, Jun, Jiang, Peng, Cejas, Paloma, Lim, Klothilda, Long, Henry, Brown, Myles, Liu, X. Shirley

“…Despite remarkable clinical efficacy of immune checkpoint blockade (ICB) in cancer treatment, ICB benefits for triple-negative breast cancer (TNBC) remain…”
Get full text

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway by Kurppa, Kari J., Liu, Yao, To, Ciric, Zhang, Tinghu, Fan, Mengyang, Vajdi, Amir, Knelson, Erik H., Xie, Yingtian, Lim, Klothilda, Cejas, Paloma, Portell, Andrew, Lizotte, Patrick H., Ficarro, Scott B., Li, Shuai, Chen, Ting, Haikala, Heidi M., Wang, Haiyun, Bahcall, Magda, Gao, Yang, Shalhout, Sophia, Boettcher, Steffen, Shin, Bo Hee, Thai, Tran, Wilkens, Margaret K., Tillgren, Michelle L., Mushajiang, Mierzhati, Xu, Man, Choi, Jihyun, Bertram, Arrien A., Ebert, Benjamin L., Beroukhim, Rameen, Bandopadhayay, Pratiti, Awad, Mark M., Gokhale, Prafulla C., Kirschmeier, Paul T., Marto, Jarrod A., Camargo, Fernando D., Haq, Rizwan, Paweletz, Cloud P., Wong, Kwok-Kin, Barbie, David A., Long, Henry W., Gray, Nathanael S., Jänne, Pasi A.

“…Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small…”
Get full text

A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer by Takeda, David Y., Spisák, Sándor, Seo, Ji-Heui, Bell, Connor, O’Connor, Edward, Korthauer, Keegan, Ribli, Dezső, Csabai, István, Solymosi, Norbert, Szállási, Zoltán, Stillman, David R., Cejas, Paloma, Qiu, Xintao, Long, Henry W., Tisza, Viktória, Nuzzo, Pier Vitale, Rohanizadegan, Mersedeh, Pomerantz, Mark M., Hahn, William C., Freedman, Matthew L.

“…Increased androgen receptor (AR) activity drives therapeutic resistance in advanced prostate cancer. The most common resistance mechanism is amplification of…”
Get full text

The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis by Pomerantz, Mark M, Li, Fugen, Takeda, David Y, Lenci, Romina, Chonkar, Apurva, Chabot, Matthew, Cejas, Paloma, Vazquez, Francisca, Cook, Jennifer, Shivdasani, Ramesh A, Bowden, Michaela, Lis, Rosina, Hahn, William C, Kantoff, Philip W, Brown, Myles, Loda, Massimo, Long, Henry W, Freedman, Matthew L

“…Matthew Freedman and colleagues show that androgen receptor (AR) binding sites undergo extensive reprogramming during prostate epithelial transformation. They…”
Get full text

Prostate cancer reactivates developmental epigenomic programs during metastatic progression by Pomerantz, Mark M., Qiu, Xintao, Zhu, Yanyun, Takeda, David Y., Pan, Wenting, Baca, Sylvan C., Gusev, Alexander, Korthauer, Keegan D., Severson, Tesa M., Ha, Gavin, Viswanathan, Srinivas R., Seo, Ji-Heui, Nguyen, Holly M., Zhang, Baohui, Pasaniuc, Bogdan, Giambartolomei, Claudia, Alaiwi, Sarah A., Bell, Connor A., O’Connor, Edward P., Chabot, Matthew S., Stillman, David R., Lis, Rosina, Font-Tello, Alba, Li, Lewyn, Cejas, Paloma, Bergman, Andries M., Sanders, Joyce, van der Poel, Henk G., Gayther, Simon A., Lawrenson, Kate, Fonseca, Marcos A. S., Reddy, Jessica, Corona, Rosario I., Martovetsky, Gleb, Egan, Brian, Choueiri, Toni, Ellis, Leigh, Garraway, Isla P., Lee, Gwo-Shu Mary, Corey, Eva, Long, Henry W., Zwart, Wilbert, Freedman, Matthew L.

“…Epigenetic processes govern prostate cancer (PCa) biology, as evidenced by the dependency of PCa cells on the androgen receptor (AR), a prostate master…”
Get full text

Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors by Cejas, Paloma, Drier, Yotam, Dreijerink, Koen M. A., Brosens, Lodewijk A. A., Deshpande, Vikram, Epstein, Charles B., Conemans, Elfi B., Morsink, Folkert H. M., Graham, Mindy K., Valk, Gerlof D., Vriens, Menno R., Castillo, Carlos Fernandez-del, Ferrone, Cristina R., Adar, Tomer, Bowden, Michaela, Whitton, Holly J., Da Silva, Annacarolina, Font-Tello, Alba, Long, Henry W., Gaskell, Elizabeth, Shoresh, Noam, Heaphy, Christopher M., Sicinska, Ewa, Kulke, Matthew H., Chung, Daniel C., Bernstein, Bradley E., Shivdasani, Ramesh A.

“…Most pancreatic neuroendocrine tumors (PNETs) do not produce excess hormones and are therefore considered ‘non-functional’ 1 – 3 . As clinical behaviors vary…”
Get full text

Chromatin accessibility promotes hematopoietic and leukemia stem cell activity by Cabal-Hierro, Lucia, van Galen, Peter, Prado, Miguel A., Higby, Kelly J., Togami, Katsuhiro, Mowery, Cody T., Paulo, Joao A., Xie, Yingtian, Cejas, Paloma, Furusawa, Takashi, Bustin, Michael, Long, Henry W., Sykes, David B., Gygi, Steven P., Finley, Daniel, Bernstein, Bradley E., Lane, Andrew A.

“…Chromatin organization is a highly orchestrated process that influences gene expression, in part by modulating access of regulatory factors to DNA and…”
Get full text

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer by Baca, Sylvan C., Takeda, David Y., Seo, Ji-Heui, Hwang, Justin, Ku, Sheng Yu, Arafeh, Rand, Arnoff, Taylor, Agarwal, Supreet, Bell, Connor, O’Connor, Edward, Qiu, Xintao, Alaiwi, Sarah Abou, Corona, Rosario I., Fonseca, Marcos A. S., Giambartolomei, Claudia, Cejas, Paloma, Lim, Klothilda, He, Monica, Sheahan, Anjali, Nassar, Amin, Berchuck, Jacob E., Brown, Lisha, Nguyen, Holly M., Coleman, Ilsa M., Kaipainen, Arja, De Sarkar, Navonil, Nelson, Peter S., Morrissey, Colm, Korthauer, Keegan, Pomerantz, Mark M., Ellis, Leigh, Pasaniuc, Bogdan, Lawrenson, Kate, Kelly, Kathleen, Zoubeidi, Amina, Hahn, William C., Beltran, Himisha, Long, Henry W., Brown, Myles, Corey, Eva, Freedman, Matthew L.

“…Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common mechanism of adaptive resistance to targeted therapy in cancer. An…”
Get full text

Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade by Gu, Shengqing Stan, Zhang, Wubing, Wang, Xiaoqing, Jiang, Peng, Traugh, Nicole, Li, Ziyi, Meyer, Clifford, Stewig, Blair, Xie, Yingtian, Bu, Xia, Manos, Michael P, Font-Tello, Alba, Gjini, Evisa, Lako, Ana, Lim, Klothilda, Conway, Jake, Tewari, Alok K, Zeng, Zexian, Sahu, Avinash Das, Tokheim, Collin, Weirather, Jason L, Fu, Jingxin, Zhang, Yi, Kroger, Benjamin, Liang, Jin Hua, Cejas, Paloma, Freeman, Gordon J, Rodig, Scott, Long, Henry W, Gewurz, Benjamin E, Hodi, F Stephen, Brown, Myles, Liu, X Shirley

“…Immune checkpoint blockade (ICB) therapy revolutionized cancer treatment, but many patients with impaired MHC-I expression remain refractory. Here, we combined…”
Get more information

FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues by Font-Tello, Alba, Kesten, Nikolas, Xie, Yingtian, Taing, Len, Varešlija, Damir, Young, Leonie S., Hamid, Anis A., Van Allen, Eliezer M., Sweeney, Christopher J., Gjini, Evisa, Lako, Ana, Hodi, F. Steven, Bellmunt, Joaquim, Brown, Myles, Cejas, Paloma, Long, Henry W.

“…Fixed-tissue ChIP-seq for H3K27 acetylation (H3K27ac) profiling (FiTAc-seq) is an epigenetic method for profiling active enhancers and promoters in…”
Get full text

Hybrid Stomach-Intestinal Chromatin States Underlie Human Barrett’s Metaplasia by Singh, Harshabad, Ha, Kyungsik, Hornick, Jason L., Madha, Shariq, Cejas, Paloma, Jajoo, Kunal, Singh, Pratik, Polak, Paz, Lee, Hwajin, Shivdasani, Ramesh A.

“…Tissue metaplasia is uncommon in adults because established cis-element programs resist rewiring. In Barrett’s esophagus, the distal esophageal mucosa acquires…”
Get full text

Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence by Wu, Zhong, Zhou, Jin, Zhang, Xiaoyang, Zhang, Zhouwei, Xie, Yingtian, Liu, Jie bin, Ho, Zandra V., Panda, Arpit, Qiu, Xintao, Cejas, Paloma, Cañadas, Israel, Akarca, Fahire Goknur, McFarland, James M., Nagaraja, Ankur K., Goss, Louisa B., Kesten, Nikolas, Si, Longlong, Lim, Klothilda, Liu, Yanli, Zhang, Yanxi, Baek, Ji Yeon, Liu, Yang, Patil, Deepa T., Katz, Jonathan P., Hai, Josephine, Bao, Chunyang, Stachler, Matthew, Qi, Jun, Ishizuka, Jeffrey J., Nakagawa, Hiroshi, Rustgi, Anil K., Wong, Kwok-Kin, Meyerson, Matthew, Barbie, David A., Brown, Myles, Long, Henry, Bass, Adam J.

“…Esophageal squamous cell carcinomas (ESCCs) harbor recurrent chromosome 3q amplifications that target the transcription factor SOX2. Beyond its role as an…”
Get full text

FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance by Li, Yihao, Qiu, Xintao, Wang, Xiaoqing, Liu, Hui, Geck, Renee C., Tewari, Alok K., Xiao, Tengfei, Font-Tello, Alba, Lim, Klothilda, Jones, Kristen L., Morrow, Murry, Vadhi, Raga, Kao, Pei-Lun, Jaber, Aliya, Yerrum, Smitha, Xie, Yingtian, Chow, Kin-Hoe, Cejas, Paloma, Nguyen, Quang-Dé, Long, Henry W., Liu, X. Shirley, Toker, Alex, Brown, Myles

“…How cancer cells adapt to evade the therapeutic effects of drugs targeting oncogenic drivers is poorly understood. Here we report an epigenetic mechanism…”
Get full text

Transcriptional Regulator CNOT3 Defines an Aggressive Colorectal Cancer Subtype by Cejas, Paloma, Cavazza, Alessia, Yandava, C N, Moreno, Victor, Horst, David, Moreno-Rubio, Juan, Burgos, Emilio, Mendiola, Marta, Taing, Len, Goel, Ajay, Feliu, Jaime, Shivdasani, Ramesh A

“…Cancer cells exhibit dramatic alterations of chromatin organization at cis-regulatory elements, but the molecular basis, extent, and impact of these…”
Get full text

Clonal tracing reveals diverse patterns of response to immune checkpoint blockade by Gu, Shengqing Stan, Wang, Xiaoqing, Hu, Xihao, Jiang, Peng, Li, Ziyi, Traugh, Nicole, Bu, Xia, Tang, Qin, Wang, Chenfei, Zeng, Zexian, Fu, Jingxin, Meyer, Cliff, Zhang, Yi, Cejas, Paloma, Lim, Klothilda, Wang, Jin, Zhang, Wubing, Tokheim, Collin, Sahu, Avinash Das, Xing, Xiaofang, Kroger, Benjamin, Ouyang, Zhangyi, Long, Henry, Freeman, Gordon J, Brown, Myles, Liu, X Shirley

“…Immune checkpoint blockade (ICB) therapy has improved patient survival in a variety of cancers, but only a minority of cancer patients respond. Multiple…”
Get full text

Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles by Cejas, Paloma, Li, Lewyn, O'Neill, Nicholas K, Duarte, Melissa, Rao, Prakash, Bowden, Michaela, Zhou, Chensheng W, Mendiola, Marta, Burgos, Emilio, Feliu, Jaime, Moreno-Rubio, Juan, Guadalajara, Héctor, Moreno, Víctor, García-Olmo, Damián, Bellmunt, Joaquim, Mullane, Stephanie, Hirsch, Michelle, Sweeney, Christopher J, Richardson, Andrea, Liu, X Shirley, Brown, Myles, Shivdasani, Ramesh A, Long, Henry W

“…Fixed-tissue chromatin immunoprecipitation sequencing (FiT-seq) enables accurate detection of histone marks on chromatin extracted from formalin-fixed…”
Get full text

Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression by Mowery, Cody T., Reyes, Jaime M., Cabal-Hierro, Lucia, Higby, Kelly J., Karlin, Kristen L., Wang, Jarey H., Kimmerling, Robert J., Cejas, Paloma, Lim, Klothilda, Li, Hubo, Furusawa, Takashi, Long, Henry W., Pellman, David, Chapuy, Bjoern, Bustin, Michael, Manalis, Scott R., Westbrook, Thomas F., Lin, Charles Y., Lane, Andrew A.

“…Down syndrome (DS, trisomy 21) is associated with developmental abnormalities and increased leukemia risk. To reconcile chromatin alterations with…”
Get full text